<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00991744</url>
  </required_header>
  <id_info>
    <org_study_id>NOPHOALL2008-DepoCyte</org_study_id>
    <nct_id>NCT00991744</nct_id>
  </id_info>
  <brief_title>Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <official_title>Phase III Randomised Study on Liposomal Cytarabine (DepoCyteÂ®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Society for Pediatric Hematology and Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordic Society for Pediatric Hematology and Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Replacement of intrathecal Triple (methotrexate, cytarabine, prednisolone) with
           intrathecal liposomal cytarabine and prednisolone during maintenance therapy will
           decrease the CNS relapse rate in high-risk ALL patients.

        -  Both acute and long-term toxicity are equal in both treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20% of children with ALL still fails to be cured. The ALL-2008 protocol is a treatment and
      research protocol that aims to improve the overall outcome of Nordic children and adolescents
      with ALL in comparison with the ALL-2000 protocol and previous NOPHO protocols.

      The specific and primary objectives of the randomised study is:

        1. To replace intrathecal triple (methotrexate, cytarabine and glucocorticosteroid) by
           intrathecal liposomal cytarabine and glucocorticosteroid during maintenance therapy in
           order to decrease the central nervous system relapse rate in high-risk acute
           lymphoblastic leukemia patients.

        2. To evaluate acute and long-term toxicity in both treatment arms.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Sterility problems in DepoCyte production
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of leukemia relapses in the central nervous system</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological toxicity</measure>
    <time_frame>6 months after cessation of leukemia therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Liposomal cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrathecal liposomal cytarabine (25 - 50 mg) combined with intrathecal prednisolone sodium succinate and oral dexamethasone 6 times during maintenance treatment for high-risk ALL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrathecal triple</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intrathecal methotrexate, cytarabine and prednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal cytarabine</intervention_name>
    <description>Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL</description>
    <arm_group_label>Liposomal cytarabine</arm_group_label>
    <other_name>Cytarbine</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine arabinoside</other_name>
    <other_name>Precortalon</other_name>
    <other_name>Di-Adreson F</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal triple</intervention_name>
    <description>Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol</description>
    <arm_group_label>Intrathecal triple</arm_group_label>
    <other_name>DepoCyte</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Precortalon</other_name>
    <other_name>Di-Adreson-F</other_name>
    <other_name>Cytarabine</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine arabinoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High risk acute lymphoblastic leukemia

          -  Not eligible for bone marrow transplantation

          -  Age 1-18

          -  Written informed consent has been obtained

        Exclusion Criteria:

          -  Persistent NCI grade 3-4 neurotoxicity from previous treatments

          -  Bilineage ALL

          -  Leukemia predisposing syndromes (e.g. Downs syndrome, Ataxia Telangiectasia)

          -  Previous cancer

          -  Known intolerance to NOPHO ALL 2008 anticancer agents

          -  Sexually active females will use safe contraceptives

          -  Previous treatment with intrathecal liposomal cytarabine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arja Harila-Saari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Reykjavik, Iceland</name>
      <address>
        <city>Reykjavik</city>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Trondheim, Norway</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Drottning Sylvias Pediatric Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Iceland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.nopho.org</url>
    <description>Home page of NOPHO - most areas are closed</description>
  </link>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>October 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2009</study_first_posted>
  <last_update_submitted>October 6, 2012</last_update_submitted>
  <last_update_submitted_qc>October 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nordic Society for Pediatric Hematology and Oncology</investigator_affiliation>
    <investigator_full_name>Arja Harila-Saari</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Central nervous system</keyword>
  <keyword>Neurotoxicity</keyword>
  <keyword>Liposomal cytarabine</keyword>
  <keyword>Children</keyword>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Childhood acute lymphoblastic leukemia</keyword>
  <keyword>Intrathecal</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

